Drug name Dosage Therapeutic action Indication Contraindication Adverse effects Nursing responsibilities

Amikacin



Drug class:
aminoglycosides

250 g IV q 12

Inhibits protein
synthesis by
binding directly to
the30S ribosomal
sub unit
;bactericidal

Primarily for short-
term treatment of
serious infections
of respiratory tract,
bones, joints, skin,
and soft tissue,
CNS (including
meningitis) and
peritonitis burns,

History of
hypersensitivity or
toxic reaction with
an aminoglycoside
antibiotic.


CNS: Neurotoxicity:
drowsiness, unsteady gait,
weakness, clumsiness,
paresthesias, tremors,
convulsions, peripheral
neuritis.

Vestibular: dizziness,
ataxia.
GI: Nausea, vomiting,
hepatotoxicity.

Metabolic: Hypokalemia,
hypomagnesemia.

Skin: Skin rash, urticaria,
pruritus, redness.

Urogenital: Oliguria,
urinary frequency,
hematuria, tubular necrosis,
azotemia.

Other: Superinfections.


1. Before initial dose, C&S;
renal function and
vestibulocochlear nerve
function

2. Monitor peak and trough
amikacin blood levels: Draw
blood 1 h after IM or
immediately after completion
of IV infusion; draw trough
levels immediately before the
next IM or IV dose.

3. Monitor & report any
changes in I&O, oliguria,
hematuria, or cloudy urine.
Keeping patient well
hydrated reduces risk of
nephrotoxicity; consult
physician regarding optimum
fluid intake.

4. Monitor for and report
auditory symptoms (tinnitus,
roaring noises, sensation of
fullness in ears, hearing loss)
and vestibular disturbances
(dizziness or vertigo,
nystagmus, ataxia).